Evidence map›Paper›PMID 36427784›Full record

ArticleTransplantation and cellular therapy2023

Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors.

Sanghee Hong, Jing Zhao, Shu Wang, Han Wang, Ji-Hyun Lee, Nosha Farhadfar, Joseph P McGuirk, Bipin N Savani, Hashmi K Shahrukh, Patrick Stiff and 22 more

Open access · greenAbstract read
In one paragraph

Article in Transplantation and cellular therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 20 institutions in 1 country.

Sanghee HongDepartment of Hematology and Oncology, University Hospitals/Case Western Reserve University, Cleveland, Ohio.
Jing ZhaoDepartment of Biostatistics, University of Florida, Gainesville, Florida.
Shu WangDepartment of Biostatistics, University of Florida, Gainesville, Florida.
Han WangDepartment of Biostatistics, University of Florida, Gainesville, Florida.
Ji-Hyun LeeDepartment of Biostatistics, University of Florida, Gainesville, Florida.
Nosha FarhadfarDivision of Hematology Oncology, Department of Medicine, University of Florida, Gainesville, Florida.
Joseph P McGuirkDivision of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Hospital, Kansas City, Kansas.
Bipin N SavaniDivision of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Hashmi K ShahrukhMayo Clinic Bone Marrow Transplant Program, Mayo Clinic, Rochester, Minnesota.
Patrick StiffDivision of Hematology & Oncology, Loyola University Medical Center, Chicago, Illinois.
Nandita KheraCollege of Medicine, Mayo Clinic, Phoenix, Arizona.
Theresa HahnDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Alison W LorenCell Therapy and Transplant Program, Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Samantha M JaglowskiJames Cancer Hospital and Solove Research Institute, Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
William A WoodDivision of Hematology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Wael SaberCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, Massachusetts.
Shernan G HoltanDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota.
Jana M ReynoldsBaylor Charles A. Sammons Cancer Center, Baylor University Medical Center at Dallas, Dallas, Texas.
Abhinav DeolDepartment of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
Heather JimDepartment of Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, Florida.
Joseph UbertiDepartment of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
Victoria WhalenDepartment of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
Jean C YiBiobehavioral Sciences Department, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jaime PreusslerNational Marrow Donor Program/Be The Match, Minneapolis, Minnesota.
K Scott BakerClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Bronwen E ShawCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Steven DevineCenter For International Blood and Marrow Transplant Research, Minneapolis, Minnesota.
Karen SyrjalaClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Navneet S MajhailSarah Cannon, Nashville, Tennessee.
John R WingardDivision of Hematology Oncology, Department of Medicine, University of Florida, Gainesville, Florida.
Zeina Al-MansourDivision of Hematology Oncology, Department of Medicine, University of Florida, Gainesville, Florida. Electronic address: Zeina.Al-Mansour@medicine.ufl.edu.
University of Florida · USFred Hutch Cancer Center · USWayne State University · USMedical College of Wisconsin · USBaylor University Medical Center · USLoyola University Medical Center · USMayo Clinic · USMayo Clinic in Florida · USMoffitt Cancer Center · USNational Marrow Donor Program · USRoswell Park Comprehensive Cancer Center · USSarah Cannon · USThe Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USThe University of Kansas Health System · USUniversity Hospitals of Cleveland · USUniversity of Massachusetts Chan Medical School · USUniversity of Minnesota · USUniversity of North Carolina at Chapel Hill · USUniversity of Pennsylvania · USVanderbilt University Medical Center · US

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
Internet Studies to Enhance Long Term Survivorship after Hematologic MalignancyR01CA160684 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI SYRJALA, KAREN LESLIE · 2011 to 2015
$3.4M
NCI NIH HHS R01 CA160684NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069294Patient-Centered Outcomes Research Institute CD-12-11-4062
6 · The paper itself

Abstract

The use of hematopoietic cell transplantation (HCT) has been increasing in older patients. However, the levels if distress, psychosocial functioning, and health-related quality of life (HRQOL) among older HCT survivors remains largely unknown. In this secondary analysis using data from 2 randomized controlled trials, we analyzed baseline Cancer and Treatment Distress (CTXD) and Confidence In Survivorship Information (CSI) surveys of HCT survivors who were age ≥60 years at the time of transplantation and alive and disease-free ≥1 year post-autologous or -allogeneic HCT. We analyzed associations of these parameters with the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores of the 12-Item Short Form Survey (SF-12) and a healthcare adherence (HCA) scale, after adjusting for transplantation and patient demographic factors. A total of 567 patients were included. The median patient age at HCT was 65 years, and 68% of the patients underwent autologous HCT. The median CTXD score was .7 (mild), and the greatest distress was reported in the "health burden" subscale. The median CSI score was 1.4 (moderate-high), with the lowest confidence reported in the "late effects" subscale. We found negative Spearman correlations between CTXD score and SF-12 PCS (P = -.59) and MCS (P = -.54) and positive Spearman correlations between CSI score and SF-12 PCS (P = .23) and MCS (P = .30). The median HCA scale score was high at .8. Male sex, autologous HCT, increased distress level, and worse CSI score were associated with lower use of preventive care. Older survivors experienced a low level of distress and moderate-high level of CSI at ≥1 year post-HCT. As lower distress and higher CSI were associated with improved HRQOL and optimized preventive HCA, CTXD/CSI measures can be used to individualize the care of older adult HCT survivors.

Indexed as

Hematopoietic Stem Cell TransplantationNeoplasmsAgedHumansMaleMiddle AgedQuality of LifeSurveys and QuestionnairesSurvivorsCancer and Treatment DistressConfidence in Survivorship InformationElderlyHealthcare adherenceHematopoietic cell transplantationHRQOLQuality of life

Identifiers

PMID36427784
PMCPMC10165614
OpenAlexW4309868422

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.